ROSARY MUNOZ: Open Payments
NPI 1073814695 · BROWNSVILLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 16 payments from 10 companies in 2025. Trend: 2023 $313 · 2024 $1,247 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 2 | $142 |
| Alkermes, Inc. | 1 | $130 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Neurocrine BioSciences, Inc. | 5 | $115 |
| ABBVIE INC. | 1 | $114 |
| Teva Pharmaceuticals USA, Inc. | 1 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| SCPHARMACEUTICALS INC. | 1 | $18 |
Products named: Auvelity, LYBALVI, CAPLYTA, REXULTI, INGREZZA, VRAYLAR, AUSTEDO XR, COBENFY.
Industry payments across TX — which companies pay providers there.
